- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT00001373
Perheellinen Välimeren kuume ja siihen liittyvät häiriöt: genetiikka ja sairauden ominaisuudet
Tutkiva tutkimus autoinflammatoristen sairauksien genetiikasta, patofysiologiasta ja luonnonhistoriasta
This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases.
The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.
Patients will undergo a medical and family history, physical examination, blood and urine tests. Additional tests and procedures may include the following:
- X-rays
- Consultations with specialists
- DNA sample collection (blood or saliva sample) for genetic studies. These might include studies of specific genes, or more complete sequencing of the genome.
- Additional blood samples a maximum of 1 pint (450 ml) during a 6-week period for studies of white cell adhesion (stickiness)
- Leukapheresis for collecting larger amounts of white cells for study. For this procedure, whole blood is collected through a needle in an arm vein. The blood flows through a machine that separates it into its components. The white cells are removed and the rest of the blood is returned to the body through another needle in the other arm.
Patients may be followed approximately every 6 months to monitor symptoms, adjust medicine dosages, and undergo routine blood and urine tests. They will receive genetic counseling by the study team on the risk of having affected children and be advised of treatment options.
Participating relatives will undergo a medical and family history, possibly with a review of medical records, physical examination, blood and urine tests. Additional procedures may include a 24-hour urine collection, X-rays, and consultations with medical specialists. A DNA sample (blood or saliva) will also be collected for genetic studies. Additional blood samples of no more than 550 mL during an 8-week period may be requested for studies of white cell adhesion (stickiness).
Relatives who have familial Mediterranean fever, TRAPS, or hyper-IgD syndrome will receive the same follow-up and counseling as described for patients above.
Normal volunteers and patients with gout will have a brief health interview and check of vital signs (blood pressure and pulse) and will provide a blood sample (up to 90 ml, or 6 tablespoons). Additional blood samples of no more than 1 pint over a 6-week period may be requested in the future....
Tutkimuksen yleiskatsaus
Tila
Yksityiskohtainen kuvaus
Study Description
This is an exploratory natural history protocol that will enroll patients with known or as yet undiagnosed disorders of inflammation. Blood, saliva, or buccal samples will be collected for genetic analysis, blood samples will be obtained for immunologic and other functional studies, a small number of subjects may undergo skin biopsy, leukapheresis, or bone marrow aspiration and biopsy, and some patients will be provided standard medical care follow up, with retrospective analysis of the clinical data gathered during follow up.
Objectives
Primary Objective: To discover the genetic basis of human disorders of inflammation.
Secondary Objective: To enumerate immunologic features and genotype-phenotype associations in specific inflammatory diseases.
Tertiary Objectives: To describe the clinical features of poorly characterized or newly defined disorders of inflammation, through the retrospective chart review of standard medical practice follow up and through the enrollment of selected subjects in separate, disease-specific protocols.
Endpoints
Primary Endpoints: The discovery of rare, high-penetrance genetic variants and common, low-penetrance genetic variants conferring susceptibility to inflammatory disease; the discovery of structural genomic variants (insertions, deletions, inversions, translocations, etc.) that cause human inflammatory disease; the discovery of common, low-penetrance germline variants that confer susceptibility to human inflammatory disease; and the discovery of somatic mutations that give rise to human inflammatory disease.
Secondary Endpoint: The description of immune cell populations, inflammatory mediators, gene expression profiling, epigenetic features, and ex vivo functional assays of leukocytes from subjects with specific inflammatory diseases.
Tertiary Endpoints: Given the wide range of inflammatory diseases, the endpoints will be formulated for specific conditions based on the clinical features of that condition.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Benjamin D Solomon, M.D.
- Puhelinnumero: (301) 402-8824
- Sähköposti: solomonb@mail.nih.gov
Tutki yhteystietojen varmuuskopiointi
- Nimi: Amanda K Ombrello, M.D.
- Puhelinnumero: (301) 827-4258
- Sähköposti: ombrelloak@mail.nih.gov
Opiskelupaikat
-
-
District of Columbia
-
Washington D.C., District of Columbia, Yhdysvallat, 20010
- Valmis
- Childrens National Medical Center
-
-
Maryland
-
Baltimore, Maryland, Yhdysvallat, 21205
- Valmis
- Johns Hopkins University
-
Bethesda, Maryland, Yhdysvallat, 20892
- Rekrytointi
- National Institutes of Health Clinical Center
-
Ottaa yhteyttä:
- NIH Clinical Center Office of Patient Recruitment (OPR)
- Puhelinnumero: TTY dial 711 800-411-1222
- Sähköposti: ccopr@nih.gov
-
Bethesda, Maryland, Yhdysvallat, 20301
- Valmis
- Walter Reed National Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Yhdysvallat, 15261
- Ei vielä rekrytointia
- University of Pittsburgh
-
Ottaa yhteyttä:
- Daniella Schwartz
- Puhelinnumero: 412-648-1587
- Sähköposti: Daniella.Schwartz@pitt.edu
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
Patients with autoinflammatory disorders and unaffected family members, and healthy volunteers.
Kuvaus
- INCLUSION CRITERIA:
There are three populations that will be included in this study: subjects with known or suspected autoinflammatory diseases, family members of subjects with known or suspected autoinflammatory diseases, and healthy controls. Persons interested in participation may be given a screening questionnaire to determine eligibility. Questions in the screening questionnaire are important to help us determine if subjects have known autoinflammatory diseases, or if there is a high clinical suspicion of autoinflammatory disease.
In order to be eligible to participate in this study as a subject with known or suspected autoinflammatory disease, an individual must meet all of the following criteria:
- Stated willingness to participate in study procedures (which at the very least includes providing a mail-in sample for genetic analysis);
- Regardless of gender, at least one month of age;
- A medical history that, in the expert opinion of the study team, is consistent with the possibility of autoinflammatory disease; and
- Ability of the subject, parents (in the case of children), or Legally Authorized Representative to understand and the willingness to sign a written informed consent document.
In order to be eligible to participate in this study as a family member of a subject with known or suspected autoinflammatory disease, an individual must meet all of the following criteria:
- Stated willingness to participate in study procedures (which at the very least includes providing a mail-in sample for genetic analysis);
- Regardless of gender, at least one month of age;
- Relationship, either by blood or marriage, to an individual enrolled or about to be enrolled in the study with known or suspected autoinflammatory disease;
- Likelihood, in the expert opinion of the study team, that analysis of a sample from the individual would advance genetic or functional analysis of the affected relative's possible autoinflammatory condition; and
- Ability of the subject, parents (in the case of children), or Legally Authorized Representative to understand and the willingness to sign a written informed consent document.
In order to be eligible to participate in this study as a healthy volunteer, an individual must meet all of the following criteria:
- Stated willingness to participate in study procedures for healthy volunteers;
- Regardless of gender, at least one year old, and not pregnant (by history of a missed menstrual period);
- Likelihood, in the expert opinion of the study team, that a sample from the individual would advance the functional analysis of an autoinflammatory condition under study; and
- Ability of the subject or parents (in the case of children) to understand and the willingness to sign a written informed consent document.
EXCLUSION CRITERIA:
For any of the three categories of subjects, an individual will be excluded from participation in this study if he or she has a medical condition that would, in the opinion of the investigators, confuse the interpretation of the study.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Havaintomallit: COHORT
- Aikanäkymät: PROSPECTIVE
Kohortit ja interventiot
Ryhmä/Kohortti |
|---|
|
Affected
Patients with auto-inflammatory disorders |
|
Family Members
Family members of patients |
|
Healthy Volunteers
Healthy Volunteers |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Genetic linkage in autoinflammatory dise
Aikaikkuna: annually
|
discovery of genetic associations to autoinflammatory disorders |
annually
|
Yhteistyökumppanit ja tutkijat
Tutkijat
- Päätutkija: Benjamin D Solomon, M.D., National Human Genome Research Institute (NHGRI)
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Aksentijevich I, Kastner DL. Genetics of monogenic autoinflammatory diseases: past successes, future challenges. Nat Rev Rheumatol. 2011 Jul 5;7(8):469-78. doi: 10.1038/nrrheum.2011.94.
- Bulua AC, Mogul DB, Aksentijevich I, Singh H, He DY, Muenz LR, Ward MM, Yarboro CH, Kastner DL, Siegel RM, Hull KM. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum. 2012 Mar;64(3):908-13. doi: 10.1002/art.33416.
- Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A, Park G, Barron KS, Weisman MH, Pashinian N, Reiff AO, Samuels J, Wright DA, Kastner DL, Lovell DJ. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012 Oct 16;157(8):533-41. doi: 10.7326/0003-4819-157-8-201210160-00003.
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvioitu)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Kipu
- Neurologiset ilmenemismuodot
- Patologiset tilat, anatomiset
- Silmäsairaudet
- Ihosairaudet
- Hikirauhasten sairaudet
- Ihosairaudet, geneettiset
- Verkkokalvon sairaudet
- Kehon lämpötilan muutokset
- Verkkokalvon rappeuma
- Hypertrofia
- Synnynnäiset, perinnölliset ja vastasyntyneiden sairaudet ja poikkeavuudet
- Patologiset tilat, merkit ja oireet
- Iho- ja sidekudostaudit
- Merkit ja oireet
- Päänsärky
- Geneettiset sairaudet, synnynnäiset
- Kuume
- Verkkokalvon dystrofiat
- Perheellinen Välimeren kuume
- Perinnölliset autoinflammatoriset sairaudet
- Splenomegalia
- Hypohidroosi
Muut tutkimustunnusnumerot
- 940105
- 94-HG-0105
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Individual genomic sequencing data and corresponding phenotype data will be deposited in dbGaP as part of the study's Genomic Data Sharing Plan. Non-genomic and/or phenotypic individual data will not be deposited in shared databases for broad research use.
IPD-jaon aikakehys
Genomic Sharing Plan in effect since 2018 with genomic data deposited to dbGaP for broad availability within six months of final data analysis of each genomic sequence. No end date of data availability through dbGaP.
IPD-jaon käyttöoikeuskriteerit
Genomic sequences will be deposited to dbGaP following final sequence analysis and available for broad use, as determined by dbGaP usage committee.
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
- ANALYTIC_CODE
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .